The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis by Têtu, Bernard et al.
Open Access
Available online http://breast-cancer-research.com/content/8/3/R28
Page 1 of 9
(page number not for citation purposes)
Vol 8 No 3 Research article
The influence of MMP-14, TIMP-2 and MMP-2 expression on 
breast cancer prognosis
Bernard Têtu1,2, Jacques Brisson3, Chang Shu Wang2, Hélène Lapointe2, Geneviève Beaudry2, 
Caty Blanchette3 and Dominique Trudel1
1Department of Pathology, Laval University, Québec, Canada
2Centre de Recherche en Cancérologie, Laval University, Québec, Canada
3Unité de Recherche en Santé des Populations, Laval University, Québec, Canada
Corresponding author: Bernard Têtu, bernard.tetu@chuq.qc.ca
Received: 3 Jun 2005 Revisions requested: 17 Aug 2005 Revisions received: 22 May 2006 Accepted: 23 May 2006 Published: 15 Jun 2006
Breast Cancer Research 2006, 8:R28 (doi:10.1186/bcr1503)
This article is online at: http://breast-cancer-research.com/content/8/3/R28
© 2006 Têtu et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Matrix metalloproteinase (MMP)-2 is very active at
degrading extracellular matrix. It is under the influence of an
activator, membrane type 1 MMP (MMP-14), and the tissue
inhibitor of metalloproteases (TIMP)-2. We hypothesized that
the individual expression of these three markers or their balance
may help to predict breast cancer prognosis.
Methods MMP-2, MMP-14 and TIMP-2 expression has been
evaluated by 35S mRNA in situ hybridization on paraffin material
of 539 breast cancers without distant metastasis at diagnosis
and with a median follow-up of 9.2 years.
Results MMP-2 and MMP-14 mRNA was detected primarily in
reactive stromal cells whereas TIMP-2 mRNA was expressed by
both stromal and cancer cells. Of the three molecules, an
adjusted Cox model revealed that high MMP-14 mRNA (≥ 10%
cells) alone predicted a significantly shorter overall survival (p =
0.031) when adjusted for clinical factors (tumor size and number
of involved lymph nodes). Prognostic significance was lost when
further adjusted for Her-2/neu and urokinase-type plasminogen
activator (p = 0.284). Furthermore, when all three components
were analyzed together, the survival was worst for patients with
high MMP-2/high MMP-14/low TIMP-2 (5 year survival = 60%)
and best with low MMP-2/low MMP-14/high TIMP-2 (5 year
survival = 74%), but the difference did not reach statistical
significance (p = 0.3285).
Conclusion Of the MMP-14/TIMP-2/MMP-2 complex, MMP-14
was the factor most significantly associated with the outcome of
breast cancer and was an independent factor of poor overall
survival when adjusted for clinical prognostic factors, but not for
certain ancillary markers.
Introduction
In breast cancer, matrix metalloproteinase (MMP)-2 is a pro-
tease produced essentially by stromal cells. In vitro studies
have clearly demonstrated that it degrades molecules that are
abundant in the extracellular matrix (ECM) [1]. MMP-2 is also
one of the major targets of recently developed synthetic MMP
inhibitors [2,3]. However, recent literature demonstrates that
the mechanism of action of MMP-2 is complex and that other
molecules modulate its activity [4,5].
M M P - 2  i s  s e c r e t e d  i n  a n  i n a c t i v e  p r o - e n z y m a t i c  f o r m  a n d ,
unlike other MMPs, its activity is modulated by tissue inhibitor
of metalloproteases (TIMP)-2 [6] and the membrane type 1
MMP (MMP-14) [7]. Using zymography, breast cancers were
found to express higher levels of activated MMP-2 than benign
lesions [8,9] and in vitro studies showed that activated MMP-
2 only is associated with an aggressive potential in breast can-
cer cell lines [10].
Animal studies showed that carcinoma cell lines transfected
with MMP-14 produced higher levels of active MMP-2 and
developed more lung metastases compared to parent tumor
cells [11]. TIMP-2 inhibits most if not all activated MMPs and
was shown to form a complex specifically with pro-MMP-2
[12]. However, the role of TIMP-2 is ambiguous since, in addi-
tion to its inhibitory effect, it is a main player in the MMP-2
bp = base-pair; ECM = extracellular matrix; HSP = heat-shock protein; MMP = matrix metalloproteinase; OS = overall survival; TIMP = tissue inhibitor 
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activation cascade [13]. However, clinical studies on breast
cancer are rare, limited in size and do not address the potential
interaction of all three factors (MMP-2, MMP-14 and TIMP-2).
This prompted us to test the hypothesis that the individual
expression or the balance between MMP-2, MMP-14 and
TIMP-2 expression may help to predict breast cancer
prognosis.
Materials and methods
Population
The patients included in this study had node-positive or node-
negative disease proven by histological examination of axillary
lymph nodes, but with absence of distant metastases at diag-
nosis. The surgery for breast carcinoma was performed
between 1 January 1980 and 31 December 1986. Clinical
information was obtained from the patients' charts by experi-
enced research nurses. The tumor size, and number of exam-
ined and positive lymph nodes were obtained from the
pathology reports. The histological types along with the histo-
logical and nuclear grades were reassessed by one of us (BT).
The project has been approved by the Laval University Ethical
Review board.
In situ hybridization
MMP-2, MMP-14 and TIMP-2 expression was analyzed by in
situ hybridization. The technique used was a modification of
the method of Wolf and colleagues [14] as described before
[15]. S35 labeled antisense RNA probes were used. Plasmids
were kindly provided by the late Prof. Paul Basset, IGBMC,
Illkirch, France (MMP-2 and MMP-14) and the late Dr Anna
Kossakowska, Calgary, Alberta (TIMP-2). cDNA inserts were
prepared from breast cancer cDNA libraries, subcloned in
pBluescript II (MMP-2 and MMP-14) and pBS KS- (TIMP-2)
vectors and were used as templates for in vitro transcription to
generate sense and anti-sense probes. The 2,124 base-pair
(bp) MMP-2 cDNA was subcloned in the EcoRI site and
extended from nucleotide 26 to 2,150; the 1,159 bp MMP-14
cDNA was subcloned in the EcoR1 site and extended from
nucleotide 454 to 1,613; and the 210 bp TIMP-2 cDNA was
subcloned in the HindIII/BamH1 site. Reduction of the probe
length was achieved by partial alkaline hydrolysis. The quality
of RNA preservation has been assessed with the use of anti-
sense RNA probes for β-actin and negative controls were
obtained with the use of sense probes. In situ hybridization for
MMP-11 and urokinase-type plasminogen activator (uPA)
were performed on all cases as previously described [15].
Immunohistochemistry
In addition to in situ hybridization, an immunohistochemical
study was performed using the avidin-biotin complex (ABC)
method as described before [15]. Studies were performed
using primary antibodies to cathepsin D (Novocastra, New-
castle, UK; dilution, 1/200), p53 (Signet Labs, Dedham, MA,
USA; ID labs, London, Ontario, Canada; dilution, 1/50), the
heat-shock protein of 27 kDa (HSP-27, Hu27, Dr Jacques
Landry, Hôtel-Dieu de Québec, Canada; dilution, 1/200), and
HER-2/neu (Triton Biosciences, Alameda, CA, USA; dilution,
1/15). For each antibody, positivity was defined by the pres-
ence of at least 10% of cells expressing the marker. P53
expression was nuclear, HER-2/neu was membranous and
HSP-27 was cytoplasmic.
Flow cytometry
DNA flow cytometric analysis was performed in all cases on
formalin fixed-paraffin embedded tissues using the method
described by Dressler and colleagues [16]. Ploidy and S-
phase fraction were determined on single parameter histo-
grams with the use of ModFit® (Verity Software House Inc.,
Topsham, ME, USA). Debris were excluded with the use of the
'Single Cut' algorithm. G0, G1 and G2 M were defined from a
Gaussian curve while S-phase fraction was evaluated with the
trapezoid model. All cases with a coefficient of variation
exceeding 8% were excluded; the coefficient of variation aver-
aged 6.1% (range 2.5% to 8.0%).
Hormone receptors
Estrogen and progesterone receptor measurement was
obtained from the patient charts. In the early 1980s, analyses
were performed using the hydroxylapatite method [17]. Posi-
tivity was defined by hormone levels above 10 fmol/mg
proteins.
Interpretation
The light microscopic interpretation of in situ hybridization was
done by two of us (BT, DT) without knowledge of the clinical
information. The scoring was assessed separately on cancer
and stromal cells using a semi-quantitative scale similar to that
used for immunohistochemistry. For each cell compartment,
the percentage of cancer or stromal cells expressing the
marker (0%, <10%, 10% to 50%, >50%) was evaluated on
the whole tumor surface of one representative section.
Statistical analysis
Distant-metastasis-free and overall survival (OS) curves were
obtained for each protease according to Kaplan and Meier
[18]. The difference between the curves was assessed using
the log-rank test [19]. Correlation between protease expres-
sion and other recognized prognostic variables in breast can-
cer was determined by the Chi-square test [19]. Distant-
metastasis-free and OS curves were generated using 10% as
the cutoff point between those expressing low (negative) or
high (positive) protease levels by stromal cells, as defined
before [15,20]. The Cox proportional hazard model was used
to evaluate the relationship between the expression of each
protease, or a combination of more than one protease, and
recurrence or death, adjusting for other known or suspected
prognostic factors [21]. Hazard ratios for the occurrence of
distant metastases or death of patients with any of the aboveAvailable online http://breast-cancer-research.com/content/8/3/R28
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combinations were obtained by univariate and multivariate
analyses.
Results
In our tumor bank, information for MMP-2 was available from
610 breast cancers, from 544 for MMP-14 and from 549
cases for TIMP-2. Results for all three molecules were availa-
ble from 539 cases and all analyses have been performed on
this group of patients. The patients' ages ranged from 29 to 72
years (average, 57.3). Of these patients, 190 (35.3%) were
node-negative, 340 (63.1%) had node invasion, and the node
status was unknown in 9 (1.6%). At last follow-up, 258
(47.9%) were alive and the follow-up of surviving patients
ranged from 5.2 to 14.6 years (average, 9.5 years); 21 (3.9%)
were lost to follow-up.
In this study, stromal cells expressed high MMP-2 (Figure 1a)
in 263 (48.8%) cases, high MMP-14 (Figure 1b) in 164
(30.4%) cases and high TIMP-2 (Figure 1c) in 200 (37.1%)
cases. Furthermore, high TIMP-2 expression by cancer cells
(Figure 1d) was present in 225 (41.7%) cases while cancer
cells expressed MMP-14 in 4 (0.7%) cases and none
expressed MMP-2.
MMP-14 expression by stromal cells was significantly associ-
ated with a younger age, lymph node involvement, a ductal his-
tology, HER-2/neu overexpression, and cathepsin D, MMP-11
(stromelysin-3) and uPA expression by stromal cells (Table 1).
MMP-2 expression by stromal cells was associated with lymph
node involvement, ductal histology, HER-2/neu and HSP-27
overexpression as well as cathepsin D, MMP-11 and uPA
expression by stromal cells. TIMP-2 expression by stromal
cells was associated with a ductal histology, and expression of
HSP-27 and uPA. TIMP-2 expression by cancer cells was
associated with peritumoral lymphovascular invasion, and
expression of HSP-27, cathepsin D and uPA by stromal cells.
Figure 2 shows the OS curves for each of the three proteases.
MMP-2 and MMP-14 expression by cancer cells was not eval-
uated because too few cases expressed those markers. No
difference in OS was found between high and low MMP-2 and
between high and low stromal and cancer TIMP-2 expression.
However, high MMP-14 expression by stromal cells predicted
a shorter survival (p = 0.05). In fact, the 5 year survival reached
72.2% for patients whose tumors had low MMP-14 levels as
opposed to 64.6% for those with high MMP-14 levels. By mul-
tivariate analysis, using the Cox model adjusting for tumor size
and number of involved lymph nodes, high MMP-14 expres-
sion was clearly a significant factor of poor survival (Table 2).
The statistical significance was lost when HER-2/neu and uPA
were included in the model. A trend was found for the associ-
ation of MMP-14 expression and metastasis-free survival (p =
0.08). Indeed, the 5 year metastasis-free survival was 64.0%
for patients with low MMP-14 as opposed to 54.3% for those
with high MMP-14.
Figure 3 shows the overall survival curve considering the bal-
ance between MMP-2, MMP-14 and TIMP-2. Of the different
combinations, OS was worst for those patients with high stro-
mal MMP-2/high stromal MMP-14/low stromal TIMP-2 (60.3%
survival at 5 years) and best with low stromal MMP-2/low stro-
mal MMP-14/high stromal TIMP-2 (74.4% survival at 5 years).
Figure 1
Expression of matrix metalloproteinase (MMP)-2, MMP-14 and tissue inhibitor of metalloproteases (TIMP)-2 in stromal and cancer cells Expression of matrix metalloproteinase (MMP)-2, MMP-14 and tissue inhibitor of metalloproteases (TIMP)-2 in stromal and cancer cells. (a) MMP-2 
expression by stromal cells (in situ hybridization, × 200); (b) MMP-14 expression by stromal cells (in situ hybridization, × 200); (c) TIMP-2 expres-
sion by stromal cells (in situ hybridization, × 200); (d) TIMP-2 expression by cancer cells (in situ hybridization, × 200). Scale bar = 200 microns. C, 
cancer cells; S, stromal cells.Breast Cancer Research    Vol 8 No 3    Têtu et al.
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Table 1
Association of high protease expression by stromal cells with other prognostic factors
Parameter Cases MMP-14 MMP-2 TIMP-2: stromal cells TIMP-2: cancer cells
Number Percentage 
Pos
p value Number Pecentage 
Pos
p value Number Percentage 
Pos
p value Number Percentage 
Pos
p value
Age years
<50 160 59 36.9 0.034 85 53.1 0.19 58 36.3 0.79 59 36.9 0.14
≥50 379 105 27.7 178 47.0 142 37.5 166 43.8
Tumor size cm
<3 297 93 31.3 0.98 146 49.2 0.65 118 39.7 0.14 122 41.1 0.83
≥3 207 65 31.4 106 51.2 69 33.3 87 42.0
Involved lymph nodes
0 190 46 24.2 81 42.6 71 37.4 80 42.1
1 to 3 166 61 36.7 0.036 93 56.0 0.041 69 41.6 0.29 75 45.2 0.52
>3 174 54 31.0 84 48.3 58 33.3 68 39.1
Peritumoral 
lymphovascular 
invasion
Yes 143 50 35.0 0.15 76 53.1 0.097 50 35.0 0.15 64 44.8 0.027
No 75 19 25.3 31 41.3 19 25.3 22 29.3
Histological grade
I 54 18 33.3 25 46.3 19 35.2 23 42.6
II 277 81 29.2 0.69 133 48.0 0.83 109 39.4 0.59 119 42.9 0.82
III 197 64 32.5 99 50.3 69 35.0 79 40.1
Nuclear grade
I 94 20 21.3 40 42.6 39 41.5 42 44.7
II 307 98 31.9 0.066 158 51.5 0.27 105 34.2 0.22 128 41.7 0.79
III 127 45 35.4 59 46.5 53 41.7 51 40.2
Histological type
Invasive ductal 
carcinoma
470 156 33.2 0.0006 238 50.6 0.021 164 34.9 0.003 28 43.1 0.83
Others 65 8 12.3 23 35.4 35 53.8 196 41.7
DNA ploidy
Diploid 143 37 25.9 0.09 64 44.8 0.18 58 40.6 0.59 60 42.0 0.99
Non-diploid 332 112 33.7 171 51.5 126 38.0 139 41.9
Estrogen receptors
Negative 143 53 37.1 0.055 76 53.1 0.22 59 41.3 0.25 61 42.7 0.89
Positive 374 106 28.3 176 47.1 134 35.8 157 42.0
Progesterone 
receptors
Negative 219 74 33.8 0.21 109 49.8 0.72 88 40.2 0.26 95 43.4 0.60
Positive 297 85 28.6 143 48.1 105 35.4 122 41.1
HER-2/neu expression
Negative 437 121 27.7 0.0042 204 46.7 0.042 158 36.2 0.34 179 41.0 0.45
Positive 102 43 42.2 59 57.8 42 41.2 46 45.1
p53Available online http://breast-cancer-research.com/content/8/3/R28
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This difference did not, however, reach significance (p  =
0.25).
Discussion
This study confirms the complexity of the role of proteases on
breast cancer prognosis. However, the prognostic influence of
MMP-2 expression is not clear in the literature. Talvensaari-
Mattila and colleagues [22], Sivula and colleagues [23] and
Pacheco and colleagues [24] are among the few investigators
who demonstrated a significant association between high
MMP-2 mRNA or protein expression levels and a poor out-
come. In our study of close to 600 cases, MMP-2 overexpres-
sion predicted a 15% greater risk of recurrence [15] but the
association of MMP-2 expression with prognosis was not sta-
tistically significant. Other studies have failed to relate MMP-2
expression to a poorer prognosis [2,15,25]. These data are
consistent with the complexity of the biology of MMP-2. In our
study, they may also be explained in part by the fact that in situ
hybridization cannot differentiate between the active and inac-
tive forms.
In our study, when each factor was taken separately, and after
adjustment for clinical prognostic factors, only MMP-14 was a
significant factor of survival, suggesting that MMP-14 may be
one of the key steps in tumor invasion and metastasis. How-
ever, the prognostic significance of MMP-14 was not inde-
pendent of HER-2/neu and uPA. This finding can be explained
by the strong regulatory interaction between HER-2/neu, uPA
and MMPs [26]. Indeed, HER-2/neu was found to induce uPA
expression and to directly up-regulate MMP expression via
transcription factor-binding sites [26].
However, the association of MMP-14 but not MMP-2 expres-
sion with survival may be explained by the fact that MMP-14
has many substrates other than MMP-2. Indeed, in vitro and
clinical studies support the major role played by MMP-14 on
ECM remodeling. MMP-14 acts either directly by degrading
ECM components such as type III collagen or indirectly by
activating pro-MMP-2 and also by inducing highly vascularized
tumors through vascular endothelial growth factor (VEGF) up-
regulation [27-30]. MMP-14 also induces functional activation
of the integrin αVβ3, which binds to MMP-2 and increases vit-
ronectin-mediated adhesion and migration of MCF7 cells [31].
Among prior clinical studies, high MMP-14 mRNA expression
was an independent factor of both tumor invasion and lymph
node metastasis in carcinoma of stomach [32], lung [33] and
cervix [34]. In breast cancer, highest expression of MMP-14 by
Negative 374 107 28.6 0.12 186 49.7 0.53 132 35.3 0.24 149 39.8 0.30
Positive 152 54 35.5 71 46.7 62 40.8 68 44.7
HSP-27
Negative 204 61 29.9 0.097 97 47.5 0.02 63 30.9 0.0024 70 34.3 0.0003
Positive 157 60 38.2 94 59.9 73 46.5 84 53.5
Cathepsin D cancer 
cells
Negative 324 94 29.0 0.29 151 46.6 0.21 111 34.3 0.071 127 39.2 0.102
Positive 207 69 33.3 87 52.2 87 42.0 96 46.4
Cathepsin D stromal 
cells
Negative 303 78 25.7 0.0035 130 42.9 0.0013 106 35.0 0.21 116 38.3 0.047
Positive 226 85 37.6 129 57.1 91 40.3 106 46.9
MMP-11
Negative 215 32 14.9 <0.0001 65 30.2 <0.0001 76 35.3 0.46 93 43.3 0.60
Positive 322 132 41.0 198 61.5 124 38.5 132 41.0
MMP-2
Negative 276 41 14.9 <0.0001 - - 89 32.2 0.017 110 39.9 0.36
Positive 263 123 46.8 - - 111 42.2 115 43.7
uPA
Negative 374 81 21.7 <0.0001 147 39.3 <0.0001 127 34.0 0.016 143 38.2 0.017
Positive 160 81 50.6 115 71.9 72 45.4 79 49.4
HSP, heat-shock protein; MMP, matrix metalloproteinase; Pos, positive; TIMP, tissue inhibitor of metalloproteases; uPA, urokinase-type plasminogen 
activator.
Table 1 (Continued)
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Figure 2
Overall survival for matrix metalloproteinase (MMP)-2, MMP-14 and tissue inhibitor of metalloproteases (TIMP)-2 expression by stromal and cancer  cells Overall survival for matrix metalloproteinase (MMP)-2, MMP-14 and tissue inhibitor of metalloproteases (TIMP)-2 expression by stromal and cancer 
cells. Overall survival curves for: (a) matrix metalloproteinase (MMP)-2 expressed by stromal cells; (b) MMP-14 expressed by stromal cells; (c) tissue 
inhibitor of metalloproteases (TIMP)-2 expressed by stromal cells; and (d) TIMP-2 expressed by cancer cells (p values obtained by the log-rank test).
Table 2
Hazard ratios for MMP-14, MMP-2, TIMP-2 and combination of MMP-14 MMP-2 TIMP-2 on breast cancer overall survival
Univariate Multivariatea Multivariateb
HR 95% CI p value HR 95% CI p value HR 95% CI p value
MMP-14 1.31 0.99–1.72 0.05 1.36 1.03–1.81 0.031 1.18 0.87–1.59 0.28
MMP-2 1.14 0.88–1.47 0.33 1.14 0.87–1.49 0.34 0.98 0.73–1.31 0.87
TIMP-2: stromal cells 0.91 0.69–1.19 0.51 1.04 0.78–1.38 0.79 0.89 0.66–1.19 0.43
TIMP-2: cancer cells 1.07 0.83–1.39 0.61 1.09 0.83–1.43 0.53 1.02 0.77–1.34 0.91
MMP-14-/MMP-2-/TIMP-2+c 1.0 1.0
MMP-14+/MMP-2+/TIMP-2- 1.46 0.89–2.38 0.13 1.29 0.77–2.16 0.33
Other categories 1.11 0.76–1.63 0.59 1.03 0.68–1.55 0.90
aCox model adjusting for tumor size and number of involved lymph nodes. bCox model adjusting for tumor size, number of involved lymph nodes, 
HER-2/neu and urokinase plasminogen activator. cTIMP-2 by stromal cells. CI, confidence interval; HR, hazard ratio; MMP, matrix metalloproteinase; 
TIMP, tissue inhibitor of metalloproteases.Available online http://breast-cancer-research.com/content/8/3/R28
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RT-PCR was found in cases with lymph node metastases
[35,36], poor clinical stage and larger tumor size [36].
In our study, MMP-14 mRNA was located in reactive stromal
cells close to cancer cells. This is consistent with data from the
literature [37] that identified MMP-14 mRNA within myofibrob-
lasts [38]. However, the location of MMP-14 in breast tissue is
debated and others found MMP-14 mRNA in cancer cells
[39]. Using immunohistochemistry, MMP-14 was located
within either stromal and/or cancer cells [40-43].
In our study, TIMP-2 did not provide independent prognostic
information. In the literature on breast cancer, the role of TIMP-
2 was controversial. This may explain contradictory results in
which patients with higher TIMP-2 expression either experi-
enced low cancer recurrence/progression [44,45] or a poor
prognosis [25,46-49], emphasizing the overall activating or
inhibitory role of TIMP-2. These contradictory findings may be
explained by the versatile role of TIMP-2 [12]. Indeed, TIMP-2
increases growth rates of murine, bovine and human cells
[50], but also inhibits tumor growth and angiogenesis in
melanoma B16F10 cells [51], attenuates migration of MDA-
MB23 breast cancer cells through a bone marrow fibroblast
monolayer [52] and abolishes the tumor-promoting effect of
fibroblasts on MCF7 cells injected with matrigel in nude mice
[53].
The relationship of survival with the combination of MMP-2,
MMP-14 and TIMP-2, although not statistically significant,
showed that survival was worst for those patients with high
MMP-2/high MMP-14/low TIMP-2 and best with low MMP-2/
low MMP-14/high TIMP-2. This lack of statistical significance
may be explained by the sample size, which may be too small
to reach significance, or by the versatile role of TIMP-2, which
may be either a favorable or an unfavorable factor. Different
combinations of proteases and protease inhibitors or activa-
tors have been investigated in the literature but clinical studies
are limited and involve few patients. Clinical studies suggest
that TIMP-2, or the ratio of MMP-2 and TIMP-2 expression,
may play a critical role on cancer progression. For example,
higher MMP-2/TIMP-2 ratios were associated with recur-
rences in patients with bladder [54] or uterine cervix [55] can-
cer. In a study on 14 patients, Onisto and colleagues [56]
report that a high MMP-2/TIMP-2 ratio correlated with lymph
node metastases in breast cancer while it predicted a better
outcome in another study [25].
Conclusion
Our data show that, of the three proteases studied, MMP-14
was most strongly associated with breast cancer prognosis
but was not independent of HER-2/neu or uPA, which may
limit its usefulness as a prognostic marker. When all three pro-
teases are studied in combination, a tendency was found for
tumors with high MMP-2, high MMP-14 and low TIMP-2
expression to predict a poor prognosis but the results did not
reach significance.
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